Management of infection and febrile neutropenia in patients with solid cancer

• J. A. Virizuela ^[7] ; J. Carratalà ^[8] ; J. M. Aguado ^[1] ; D. Vicente ^[7] ; M. Salavert ^[9] ; M. Ruiz ^[2] ; I. Ruiz ^[2] ; F. Marco ^[10] ; M. Lizasoain ^[1] ; P. Jiménez-Fonseca ^[3] ; C. Gudiol ^[8] ; J. Cassinello ^[4] ; A. Carmona-Bayonas ^[5] ; M. Aguilar ^[6] ; J. J. Cruz ^[11]
  1. [1] Hospital Universitario 12 de Octubre

     Hospital Universitario 12 de Octubre

     Madrid, España

     
  2. [2] Hospital Vall d'Hebron

     Hospital Vall d'Hebron

     Barcelona, España

     
  3. [3] Hospital Universitario Central de Asturias

     Hospital Universitario Central de Asturias

     Oviedo, España

     
  4. [4] Hospital Universitario de Guadalajara

     Hospital Universitario de Guadalajara

     Guadalajara, España

     
  5. [5] Hospital Morales Meseguer

     Hospital Morales Meseguer

     Murcia, España

     
  6. [6] Hospital Universitario Virgen del Rocío

     Hospital Universitario Virgen del Rocío

     Sevilla, España

     
  7. [7] Hospital Universitario Virgen de Macarena, Sevilla, España
  8. [8] Hospital Universitari de Bellvitge-IDIBELL, España
  9. [9] Hospital Universitari i Politècnic La Fe, España
  10. [10] Hospital Clínic, Barcelona, España
  11. [11] Hospital Clínico Universitario de Salamanca, España

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 18, Nº. 6 (June 2016), 2016, págs. 557-570
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • An expert group from the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC, for its acronym in Spanish) and the Spanish Society of Medical Oncology (SEOM, for its acronym in Spanish) have reviewed the main aspects to be considered when evaluating patients with solid cancer and infectious complications contained in this article. Recommendations have, therefore, been put forth regarding the prophylaxis of the most prevalent infections in these patients, the use of vaccines, measures to control infection through vascular catheters, and preventing infection in light of certain surgical maneuvers. The following is a revision of the criteria for febrile neutropenia management and the use of colony-stimulating factors and closes with several guidelines for treating the cancer patient with serious infection. The document concludes with a series of measures to control hospital infection.